FrancophonIA/ELRC3.0 huggingface dataset:
English: This product information has been updated to include the results of studies with Ilaris in the paediatric population.
Croatian: Ovaj je sažetak ažuiriran kako bi uključivao rezultate ispitivanja s Ilarisom u pedijatrijskoj populaciji.
English: Your baby should not receive live vaccines until at least 16 weeks after you received your last dose of canakinumab before giving birth.
Croatian: Vaše dijete ne smije primiti živa cjepiva dok ne prođe najmanje 16 tjedana od Vaše zadnje doze kanakinumaba koju ste primili prije poroda.
English: Still's disease including AOSD and SJIA is an inflammatory disease that can cause pain, swelling and inflammation of one or more joints, as well as rash and fever.
Croatian: Stillova bolest, uključujući SBOD i SJIA, je upalna bolest koja može uzrokovati bol, oticanje i upalu jednog ili više zglobova, kao i osip i vrućicu.
English: In the Phase I/II study, treatment with canakinumab had a rapid onset of action, with disappearance or clinically significant improvement of symptoms within one day after dosing.
Croatian: U ispitivanju faze I/II liječenje kanakinumabom imalo je brzi nastup djelovanja, uz nestanak ili klinički značajno poboljšanje simptoma u roku od jednog dana od primitka doze.
English: The Marketing Authorisation Holder has completed four Paediatric Investigation Plans for Ilaris (for CAPS, SJIA, FMF - HIDS/MKD and TRAPS respectively).
Croatian: Nositelj odobrenja dovršio je četiri Plana pedijatrijskih ispitivanja za Ilaris (za CAPS, SJIA, FMFHIDS/MKD odnosno TRAPS).
English: What Ilaris is used for Ilaris is used for treatment of the following inflammatory diseases: - Periodic fever syndromes:
Croatian: Za što se koristi Ilaris Ilaris se koristi za liječenje sljedećih upalnih bolesti: - sindromi periodičnih vrućica:
English: If not used immediately, the solution should be stored in the refrigerator (2°C - 8°C) and used within 24 hours.
Croatian: Ako se ne upotrijebi odmah, otopinu je potrebno čuvati u hladnjaku (2°C - 8°C) i upotrijebiti u roku od 24 sata.
English: In an exploratory analysis of the primary endpoint, it was observed that in patients with an inadequate response after the first dose, an up-titration within the first month to a dose of 300 mg (or 4 mg/kg) every 4 weeks further improved flare control, reduced disease activity and normalised CRP and SAA levels.
Croatian: U eksploratornoj analizi primarne mjere ishoda opaženo je da je u bolesnika s nedostatnim odgovorom nakon prve doze postupno povećanje doze unutar prvog mjeseca do doze od 300 mg (ili 4 mg/kg) svaka 4 tjedna dodatno poboljšalo kontrolu razbuktavanja, smanjilo aktivnost bolesti i normaliziralo razine CRP-a i SAA.
English: Gouty arthritis: If you have a gouty arthritis attack, you will be given a single dose of Ilaris.
Croatian: Urični artritis: Ako imate napad uričnog artritisa, dobit ćete jednokratnu dozu Ilarisa.
English: For gouty arthritis, the physician should be experienced in the use of biologics and Ilaris should be administered by a healthcare professional.
Croatian: Za urični artritis, liječnik mora imati iskustva s primjenom bioloških lijekova te Ilaris mora primjenjivati zdravstveni djelatnik.
English: The safety profile of canakinumab appeared similar to that in patients aged 2 years and above.
Croatian: Sigurnosni profil kanakinumaba činio se sličan onome u bolesnika u dobi od 2 i više godina.
English: A total of 225 patients were treated with subcutaneous canakinumab 150 mg and 229 patients were treated with intramuscular triamcinolone acetonide (TA) 40 mg at study entry, and when experiencing a new attack thereafter.
Croatian: Ukupno je 225 bolesnika liječeno supkutanim kanakinumabom 150 mg, a 229 bolesnika je liječeno intramuskularnim triamcinolon acetonidom (TA) 40 mg na početku ispitivanja, te nakon toga u slučaju novog napada.
English: Transient and asymptomatic cases of elevations of serum transaminases or bilirubin have been reported in clinical trials (see section 4.8).
Croatian: U kliničkim ispitivanjima zabilježeni su prolazni i asimptomatski slučajevi povišenja serumskih transaminaza ili bilirubina (vidjeti dio 4.8).
English: • 150 mg for patients who weigh more than 40 kg
Croatian: • 150 mg za bolesnike koji su teži od 40 kg
English: Resolution of disease flare was achieved by week 5 and the patient had not experienced any new flare at the end of Part II of the study (week 16).
Croatian: Povlačenje razbuktavanja bolesti postignuto je do 5. tjedna i bolesnik nije doživio nikakvo novo razbuktavanje bolesti na kraju II. dijela ispitivanja (16. tjedan).
English: In the overall study population, patients on ULT had a less pronounced treatment difference in both pain reduction and reduction in the risk of subsequent gouty arthritis attacks compared to patients not on ULT.
Croatian: U cjelokupnoj ispitivanoj populaciji bolesnici koji su primali ULT imali su manje izraženu terapijsku razliku kako u smanjenju boli tako i u smanjenju rizika od naknadnih napada artritisa u usporedbi s bolesnicima koji nisu primali ULT.
English: The apparent volume of distribution per kg (V/F per kg) was 0.14 l/kg.
Croatian: Prividni volumen distribucije po kg (V/F po kg) bio je 0,14 l/kg.
English: Find a clean place in which to prepare and administer the injection.
Croatian: Pronađite čisto mjesto na kojem ćete pripremiti i primijeniti injekciju.
English: The co-primary endpoints were: (i) gouty arthritis pain intensity (visual analogue scale, VAS) at 72 hours post-dose, and (ii) time to first new gouty arthritis attack.
Croatian: Suprimarne mjere ishoda bile su: (I) intenzitet boli uričnog artritisa (vizualna analogna skala, VAS) 72 sata nakon doze te (II) vrijeme do prvog novog napada uričnog artritisa.
English: Part II: In the withdrawal period of the pivotal study, the primary endpoint was defined as the proportion of patients with a disease relapse/flare: none (0%) of the patients randomised to canakinumab flared, compared with 81% of the patients randomised to placebo.
Croatian: II. dio: U razdoblju ustezanja u ključnom ispitivanju primarna mjera ishoda bila je definirana kao udio bolesnika s relapsom/razbuktavanjem bolesti: nijedan (0%) od bolesnika randomiziranih na kanakinumab nije imao razbuktavanje bolesti, u usporedbi s 81% bolesnika randomiziranih na placebo.
English: Ilaris is used in adults to treat the symptoms of frequent gouty arthritis attacks if other treatments have not worked well enough.
Croatian: Ilaris se primjenjuje kod odraslih osoba za liječenje simptoma učestalih napada uričnog artritisa ako ostale terapije nisu dovoljno dobro djelovale.
English: If a patient becomes neutropenic or leukopenic, the WBC counts should be monitored closely and treatment discontinuation should be considered.
Croatian: Ako se kod bolesnika javi neutropenija ili leukopenija, broj Lkc treba pažljivo kontrolirati te razmotriti prekid liječenja.
English: There were no antibodies against Ilaris observed in TRAPS, HIDS/MKD and FMF patients treated with doses of 150 mg and 300 mg over 16 weeks of treatment.
Croatian: Nije bilo protutijela protiv Ilarisa opaženih u bolesnika s TRAPS-om, HIDS/MKD-om i FMF-om liječenih dozama od 150 mg i 300 mg tijekom 16 tjedana liječenja.
English: Gouty arthritis is caused by the formation of urate crystals.
Croatian: Urični artritis je uzrokovan stvaranjem kristala urata u tijelu.
English: Carefully withdraw the required volume depending on the dose to be administered (0.1 ml to 1 ml) and subcutaneously inject using a 27 G x 0.5 inch (13 mm) needle.
Croatian: Pažljivo izvucite potreban volumen ovisno o dozi koju treba primijeniti (0,1 ml do 1 ml) i injicirajte supkutano koristeći iglu od 27 G x 13 mm.
English: Never re-use the leftover solution.
Croatian: Nikada nemojte ponovno upotrebljavati preostalu otopinu.
English: Overall, 33% (25/75) of patients randomised to dose reduction or dose interval prolongation arms were able to discontinue treatment with canakinumab and maintain inactive disease status for 6 months.
Croatian: Općenito, 33% (25/75) bolesnika randomiziranih na smanjenje doze ili produljenje intervala doziranja uspjeli su prekinuti liječenje kanakinumabom i održati status neaktivne bolesti 6 mjeseci.
English: Significant improvements were seen in physician's clinical assessment of autoinflammatory disease activity: global assessment of autoinflammatory disease activity, assessment of skin disease (urticarial skin rash), arthralgia, myalgia, headache/migraine, conjunctivitis, fatigue/malaise, assessment of other related symptoms, and patient's assessment of symptoms.
Croatian: Značajna poboljšanja uočena su u liječnikovoj kliničkoj procjeni aktivnosti autoinflamatorne bolesti: ukupna procjena aktivnosti autoinflamatorne bolesti, procjena kožne bolesti (urtikarijski kožni osip), artralgija, mijalgija, glavobolja/migrena, konjunktivitis, umor/malaksalost, procjena drugih povezanih simptoma i bolesnikova procjena simptoma.
English: Use of canakinumab with TNF inhibitors is not recommended because this may increase the risk of serious infections.
Croatian: Primjena kanakinumaba s inhibitorima TNF-a ne preporučuje se zato što bi mogla povećati rizik od ozbiljnih infekcija.
English: - Keep this medicine out of the sight and reach of children.
Croatian: Lijek čuvajte izvan pogleda i dohvata djece.
English: After repeated subcutaneous administration of 150 mg every 4 weeks, canakinumab minimal concentration at week 16 (Cmin) was estimated to be 15.4 ± 6.6 g/ml.
Croatian: Nakon ponovljene supkutane primjene 150 mg svaka 4 tjedna, procijenjeno je da minimalna koncentracija kanakinumaba u 16. tjednu (Cmin) iznosi 15,4 ± 6,6 g/ml.
English: No data are available on the risk of secondary transmission of infection by live (attenuated) vaccines in patients receiving canakinumab.
Croatian: Nema dostupnih podataka o riziku od sekundarnog prijenosa infekcije živim (atenuiranim) cjepivima kod bolesnika koji primaju kanakinumab.
English: Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with rheumatic conditions, in particular Still's disease.
Croatian: Sindrom aktivacije makrofaga (engl. macrophage activation syndrome; MAS) poznat je, po život opasan poremećaj koji se može razviti u bolesnika s reumatskim bolestima, osobito Stillovom bolešću.
English: Of the patients in clinical remission who continued with further dose reduction (1 mg/kg every 4 weeks) or dose interval prolongation (4 mg/kg every 12 weeks), 93% (26/28) and 91% (30/33) of patients, respectively, were able to maintain inactive disease status for 6 months.
Croatian: Od bolesnika u kliničkoj remisiji koji su nastavili s dodatnim smanjenjem doze (1 mg/kg svaka 4 tjedna) ili produljenjem intervala doziranja (4 mg/kg svakih 12 tjedana), 93% (26/28), odnosno 91% (30/33) bolesnika uspjelo je održati status neaktivne bolesti 6 mjeseci.
English: Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.
Croatian: Kanakinumab se veže visokim afinitetom specifično za humani IL-1 beta i neutralizira biološku aktivnost humanog IL-1 beta tako što blokira njegovu interakciju s receptorima za IL-1 te tako sprječava aktivaciju gena koju inducira IL-1 beta i stvaranje upalnih posrednika.
English: Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks (see section 4.5).
Croatian: Stoga se živa cjepiva ne smiju davati istodobno s kanakinumabom, osim ako koristi očigledno ne premašuju rizike (vidjeti dio 4.5).
English: Formal carcinogenicity studies have not been conducted with canakinumab.
Croatian: Formalna ispitivanja kancerogenosti nisu se provodila s kanakinumabom.
English: Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks.
Croatian: Stoga se živa cjepiva ne smiju davati istodobno s kanakinumabom osim ako je jasno da koristi premašuju rizike.
English: The mean change in pain score among canakinumab treated patients was consistent at day 29.
Croatian: Srednja promjena u rezultatu za bol među bolesnicima liječenim kanakinumabom bila je dosljedna nakon 29 dana.
English: The most frequent adverse drug reactions were infections predominantly of the upper respiratory tract.
Croatian: Najučestalije nuspojave na lijek bile su infekcije pretežno gornjeg dijela dišnog sustava.
English: Concomitant use of canakinumab with tumour necrosis factor (TNF) inhibitors is not recommended because this may increase the risk of serious infections (see section 4.5).
Croatian: Istodobna primjena kanakinumaba s inhibitorima tumor nekrotizirajućeg faktora (TNF) se ne preporučuje jer bi to moglo povećati rizik od ozbiljnih infekcija (vidjeti dio 4.5).
English: It is not known whether Ilaris passes into human milk.
Croatian: Nije poznato izlučuje li se Ilaris u majčino mlijeko.
English: Although reductions in platelet count (≥ Grade 2) occurred in 0.6% of patients, bleeding has not been identified as an adverse reaction.
Croatian: Iako su se smanjenja broja trombocita (≥ stupnja 2) javila u 0,6% bolesnika, krvarenje nije utvrđeno kao nuspojava.
English: The incidence of patients with triglyceride elevations > 5 x upper limit of normal (ULN) was 2.4% with canakinumab and 0.7% with triamcinolone acetonide.
Croatian: Incidencija bolesnika s povišenjima triglicerida >5 x gornja granica normale (GGN) bila je 2,4% s kanakinumabom i 0,7% s triamcinolon acetonidom.
English: Experience from individual patients who achieved a complete response following dose escalation to 600 mg (8 mg/kg) every 8 weeks suggests that a higher dose may be beneficial in patients not achieving complete response or not maintaining complete response with the recommended doses (150 mg or 2 mg/kg for patients ≥ 15 kg and ≤ 40 kg).
Croatian: Iskustvo s pojedinačnim bolesnicima koji su postigli potpuni odgovor nakon povećanja doze na 600 mg (8 mg/kg) svakih 8 tjedana upućuje na to da bi viša doza mogla biti korisna kod bolesnika koji ne postignu potpun odgovor ili ne održavaju potpun odgovor s preporučenim dozama (150 mg ili 2 mg/kg za bolesnike ≥15 kg i ≤40 kg).
English: - Any unused medicine must be discarded after the dose has been injected.
Croatian: Sav neiskorišteni lijek mora se baciti nakon ubrizgavanja doze.
English: Gouty arthritis There is no relevant use of Ilaris in the paediatric population in the indication gouty arthritis.
Croatian: Urični artritis Nema relevantne primjene Ilarisa u pedijatrijskoj populaciji u indikaciji uričnog artritisa.
English: The active substance is canakinumab.
Croatian: Djelatna tvar je kanakinumab.
English: A murine antimurine IL-1 beta antibody had no undesirable effects on fertility in male or female mice (see section 5.3).
Croatian: Protutijelo na mišji IL-1 beta nije imalo neželjenih učinaka na plodnost mužjaka ili ženki miševa (vidjeti dio 5.3).
English: Treatment with Ilaris may result in dizziness/vertigo or asthenia (see section 4.8).
Croatian: Liječenje Ilarisom može rezultirati omaglicom/vrtoglavicom ili astenijom (vidjeti dio 4.8).
English: Patients taking canakinumab in Part II had a 64% reduced risk of a flare event as compared to the placebo group (hazard ratio of 0.36; 95% CI: 0.17 to 0.75; p=0.0032).
Croatian: Bolesnici koji su uzimali kanakinumab u drugom dijelu imali su za 64% smanjeni rizik od naglog pogoršanja bolesti u usporedbi s placebo skupinom (omjer hazarda 0,36; 95% CI: 0,17 do 0,75; p=0,0032).
English: The expression of hepatic CYP450 enzymes may be suppressed by the cytokines that stimulate chronic inflammation, such as interleukin-1 beta (IL-1 beta).
Croatian: Ekspresiju jetrenih CYP450 enzima mogu potisnuti citokini koji stimuliraju kroničnu upalu, poput interleukina-1 beta (IL-1 beta).
English: Two non-randomised HIDS/MKD patients aged > 28 days but < 2 years were included in the study and received canakinumab.
Croatian: Dva nerandomizirana bolesnika s HIDS/MKD-om u dobi od >28 dana ali <2 godine bila su uključena u ispitivanje i primala kanakinumab.
English: Tip the vial to ensure that the required amount of solution can be drawn into the syringe.
Croatian: Nagnite bočicu kako biste osigurali da se potrebna količina otopine može uvući u štrcaljku.
English: Although ≥ Grade 2 reductions in neutrophil count occurred in 6.5% of patients (common) and Grade 1 reductions occurred in 9.5% of patients, the reductions are generally transient and neutropenia-associated infection has not been identified as an adverse reaction.
Croatian: Iako su se smanjenja broja neutrofila ≥ stupnja 2 javila u 6,5% bolesnika (često), a smanjenja stupnja 1 u 9,5% bolesnika, smanjenja su općenito prolazna te infekcija povezana s neutropenijom nije utvrđena kao nuspojava.
English: The estimated steady state AUCtau was 636.7 ± 260.2 μg*d/ml.
Croatian: Procijenjeni AUCtau u stanju dinamičke ravnoteže bio je 636,7 ± 260,2 μg*d/ml.
English: Hold the syringe at a 90-degree angle and in a single, smooth motion, push the needle straight down completely into the skin.
Croatian: Držite štrcaljku pod kutom od 90 stupnjeva i jednim glatkim pokretom do kraja gurnite iglu okomito prema dolje u kožu.
English: The overall predicted mean (±SD) for Cmin,ss, Cmax,ss and AUC,ss4w were 14.7±8.8 μg/ml, 36.5 ± 14.9 μg/ml and 696.1 ± 326.5 μg*d/ml, respectively.
Croatian: Ukupne predviđene srednje vrijednosti (±SD) za Cmin,ss, Cmax,ss i AUC,ss4w bile su 14,7±8,8 μg/ml, 36,5 ± 14,9 μg/ml odnosno 696,1 ± 326,5 μg*d/ml.
English: A 6-year observational registry study was conducted to provide data on the long-term safety and effectiveness of canakinumab treatment in paediatric and adult CAPS patients in routine clinical practice.
Croatian: Provedeno je 6-godišnje opservacijsko ispitivanje u obliku registra (opservacijski registar) kako bi se dobili podaci o dugoročnoj sigurnosti i učinkovitosti liječenja kanakinumabom pedijatrijskih i odraslih bolesnika s CAPS-om u rutinskoj kliničkoj praksi.
English: Seventeen patients (including 6 patients under the age of 2 years) were evaluated, using weight-based starting doses of 2-8 mg/kg.
Croatian: Bilo je ocijenjeno sedamnaest bolesnika (uključujući 6 bolesnika mlađih od 2 godine) uz početne doze od 2-8 mg/kg temeljene na tjelesnoj težini.
English: Make sure all of the solution is in the bottom of the vial.
Croatian: 13. Provjerite da je cjelokupna otopina na dnu bočice.
English: Disease activity was rated as absent or mild/moderate in more than 90% of patients at all post-baseline time points in the study, and median serological markers of inflammation (CRP and SAA) were normal (< 10 mg/litre) at all post-baseline time points.
Croatian: Aktivnost bolesti je bila ocijenjena kao odsutna ili blaga/umjerena u više od 90% bolesnika u svim ispitivanim vremenskim točkama nakon početka ispitivanja i srednja vrijednost seroloških upalnih markera (CRP i SAA) je bila normalna (<10 mg/litra) u svim ispitivanim vremenskim točkama nakon početka.
English: Turn the vial and syringe upside down and bring to eye level.
Croatian: Preokrenite bočicu sa štrcaljkom naopako i podignite je do razine očiju.
English: Allow to stand for about 15 minutes at room temperature to get a clear to opalescent solution.
Croatian: Pustite da odstoji oko 15 minuta na sobnoj temperaturi kako biste dobili bistru do opalescentnu otopinu.
English: In the long-term, open-label studies with dose escalation, events of infections (gastroenteritis, respiratory tract infection, upper respiratory tract infection), vomiting and dizziness were more frequently reported in the 600 mg or 8 mg/kg dose group than in other dose groups.
Croatian: U dugoročnim, otvorenim ispitivanjima s eskalacijom doze pojave infekcija (gastroenteritis, infekcija dišnog sustava, infekcija gornjeg dijela dišnog sustava), povraćanja i omaglice bile su češće u skupini koja je primala dozu od 600 mg ili 8 mg/kg nego u ostalim doznim skupinama.
English: What Ilaris contains
Croatian: Što Ilaris sadrži
English: The aim of the study was to assess efficacy, safety, and tolerability of canakinumab (150 mg or 2 mg/kg every 8 weeks) in patients with CAPS.
Croatian: Cilj ispitivanja bio je ocijeniti djelotvornost, sigurnost i podnošljivost kanakinumaba (150 mg ili 2 mg/kg svakih 8 tjedana) kod bolesnika s CAPS-om.
English: The safety and efficacy of Ilaris in SJIA patients under 2 years of age have not been established.
Croatian: Sigurnost i djelotvornost Ilarisa u bolesnika sa SJIA-om mlađih od 2 godine nije ustanovljena.
English: After 24 weeks, 71% (27/38) of patients who received the reduced dose (2 mg/kg every 4 weeks) and 84% (31/37) of patients who received the prolonged dosing interval (4 mg/kg every 8 weeks) were able to maintain inactive disease status for 6 months.
Croatian: Nakon 24 tjedna, 71% (27/38) bolesnika koji su primali smanjenu dozu (2 mg/kg svaka 4 tjedna) i 84% (31/37) bolesnika koji su imali produljeni interval doziranja (4 mg/kg svakih 8 tjedana) uspjelo je održati status neaktivne bolesti 6 mjeseci.
English: In clinical studies, CAPS, TRAPS, HIDS/MKD and FMF patients who have uncontrolled overproduction of IL-1 beta show a rapid and sustained response to therapy with canakinumab, i.e. laboratory parameters such as high C-reactive protein (CRP) and serum amyloid A (SAA), high neutrophil and platelet counts, and leukocytosis rapidly returned to normal.
Croatian: U kliničkim ispitivanjima bolesnici s CAPS-om, TRAPS-om, HIDS/MKD-om i FMF-om koji imaju nekontrolirano prekomjerno stvaranje IL-1 beta pokazuju brzi i održani odgovor na terapiju kanakinumabom, tj. povratak na normalne vrijednosti laboratorijskih parametara poput C-reaktivnog proteina (CRP) i serumskog amiloida A (SAA), visokog broja neutrofila i trombocita te leukocitoze.
English: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Croatian: Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti u skladu s lokalnim propisima.
English: If you received canakinumab while you were pregnant, it is important that you inform the baby's doctor or nurse before any vaccinations are given to your baby.
Croatian: Ako ste primili kanakinumab tijekom trudnoće, važno je da o tome obavijestite djetetovog liječnika ili medicinsku sestru prije nego
English: Other activators of the innate immune system, such as endogenous agonists of toll-like receptors, may contribute to the transcriptional activation of the IL1 beta gene, initiating a gouty arthritis attack.
Croatian: Drugi aktivatori prirođenog imunološkog sustava, kao što su endogeni agonisti receptora sličnih Tollu, mogu doprinijeti transkripcijskoj aktivaciji IL-1 beta gena te započeti napad uričnog artritisa.
English: Live vaccines: You are advised to avoid being vaccinated with a type of vaccine called a live vaccine while you are being treated with Ilaris.
Croatian: Živa cjepiva: preporučuje se da izjegavate cijepljenje vrstom cjepiva koje se naziva živim cjepivom dok se liječite Ilarisom.
English: • Patient Reminder Card
Croatian: • Kartica s podsjetnikom za bolesnika
English: Antibodies against Ilaris were observed in approximately 1.5%, 3% and 2% of the patients treated with Ilaris for CAPS, SJIA and gouty arthritis, respectively.
Croatian: Protutijela protiv Ilarisa uočena su u otprilike 1,5%, 3% i 2% bolesnika liječenih Ilarisom zbog CAPSa, SJIA te u 2% bolesnika liječenih Ilarisom zbog uričnog artritisa.
English: Macrophage activation syndrome in patients with Still's disease
Croatian: Sindrom aktivacije makrofaga u bolesnika sa Stillovom bolešću
English: Periodic fever syndromes Ilaris is used in adults and children aged 2 years and older to treat the following: - Cryopyrin-associated periodic syndromes (CAPS) - this is a group of auto-inflammatory diseases, which include:
Croatian: Ilaris se primjenjuje u odraslih osoba i djece u dobi od 2 i više godina za liječenje sljedećeg: periodičnih sindroma povezanih s kriopirinom (CAPS) - to je skupina autoinflamatornih bolesti koja uključuje:
English: Abnormal kidney function test results (creatinine renal clearance decreased, proteinuria).
Croatian: Poremećeni rezultati testa bubrežne funkcije (smanjeni bubrežni klirens kreatinina, proteinurija).